Bio-Path Q3 net loss $3.2M; positive prexigebersen AML Phase 2 data

BIO-PATH HOLDINGS, INC.

2023-Q3 EPS reported -$1.47

Net loss of $3.2M ($0.32/sh) vs $3.5M ($0.49/sh) in Q3 2022, improvement from lower expenses and warrant income.
Cash $2.4M as of Sep 30, 2023, down from $10.4M at Dec 31, 2022; net cash used in ops $9.7M in nine months.
Positive Phase 2 interim data for prexigebersen in AML; results exceed outcomes of decitabine/venetoclax alone.
R&D expense $2.3M (down from $2.4M), G&A $1.0M (down from $1.2M) year-over-year.
KOL event in October with MD Anderson and Georgia Cancer Center experts discussing prexigebersen potential.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

BIO-PATH HOLDINGS, INC. reported third quarter ended September 30, 2023 results: net income net loss of $3.2 million, or $0.32 per share, EPS $0.32 per share.

Period: third quarter ended September 30, 2023
Net income: net loss of $3.2 million, or $0.32 per share
EPS: $0.32 per share
Result: reported results

Exact text from the filing

The Company reported a net loss of $3.2 million, or $0.32 per share, for the three months ended September 30, 2023, compared to a net loss of $3.5 million, or $0.49 per share, for the three months ended September 30, 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

BIO-PATH HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-019085

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.